Free Trial

Agios Pharmaceuticals (AGIO) Stock Forecast & Price Target

Agios Pharmaceuticals logo
$35.42 -0.39 (-1.09%)
(As of 12/20/2024 05:40 PM ET)

Agios Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
4

Based on 8 Wall Street analysts who have issued ratings for Agios Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 4 have given a hold rating, and 4 have given a buy rating for AGIO.

Consensus Price Target

$56.33
59.04% Upside
According to the 8 analysts' twelve-month price targets for Agios Pharmaceuticals, the average price target is $56.33. The highest price target for AGIO is $75.00, while the lowest price target for AGIO is $46.00. The average price target represents a forecasted upside of 59.04% from the current price of $35.42.
Get the Latest News and Ratings for AGIO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Agios Pharmaceuticals and its competitors.

Sign Up

AGIO Analyst Ratings Over Time

TypeCurrent Forecast
12/22/23 to 12/21/24
1 Month Ago
11/22/23 to 11/21/24
3 Months Ago
9/23/23 to 9/22/24
1 Year Ago
12/22/22 to 12/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$56.33$52.33$51.33$35.20
Forecasted Upside59.04% Upside-5.77% Downside10.28% Upside47.03% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

AGIO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AGIO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Agios Pharmaceuticals Stock vs. The Competition

TypeAgios PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside59.04% Upside25,828.55% Upside14.54% Upside
News Sentiment Rating
Neutral News

See Recent AGIO News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/18/2024Cantor Fitzgerald
4 of 5 stars
 Reiterated RatingOverweight ➝ Overweight
12/10/2024Royal Bank of Canada
4 of 5 stars
 Boost TargetOutperform ➝ Outperform$55.00 ➝ $57.00+15.90%
12/9/2024Scotiabank
5 of 5 stars
G. Harrison
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetSector Outperform ➝ Sector Outperform$53.00 ➝ $75.00+44.40%
10/10/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Brill
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$51.00+24.39%
9/27/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Berens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
9/27/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$60.00 ➝ $56.00+16.55%
6/13/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$46.00-1.65%
6/4/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$33.00 ➝ $53.00+15.49%
5/5/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$37.00 ➝ $34.00+30.57%
2/3/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$41.00+35.85%
2/3/2023Piper Sandler Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$41.00+35.85%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:46 AM ET.


AGIO Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Agios Pharmaceuticals is $56.33, with a high forecast of $75.00 and a low forecast of $46.00.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AGIO shares.

According to analysts, Agios Pharmaceuticals's stock has a predicted upside of 59.04% based on their 12-month stock forecasts.

Over the previous 90 days, Agios Pharmaceuticals's stock had 2 downgrades by analysts.

Agios Pharmaceuticals has been rated by research analysts at Cantor Fitzgerald, Leerink Partners, Leerink Partnrs, Raymond James, Royal Bank of Canada, and Scotiabank in the past 90 days.

Analysts like Agios Pharmaceuticals less than other "medical" companies. The consensus rating score for Agios Pharmaceuticals is 2.50 while the average consensus rating score for "medical" companies is 2.81. Learn more on how AGIO compares to other companies.


This page (NASDAQ:AGIO) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners